Provided by Tiger Fintech (Singapore) Pte. Ltd.

SITC

19.940
+0.7403.85%
Volume:5.59M
Turnover:110.73M
Market Cap:53.58B
PE:6.61
High:20.050
Open:19.040
Low:19.040
Close:19.200
Loading ...

At HK$21.20, Is It Time To Put SITC International Holdings Company Limited (HKG:1308) On Your Watch List?

Simply Wall St.
·
10 Dec 2024

Why We Like The Returns At SITC International Holdings (HKG:1308)

Simply Wall St.
·
25 Nov 2024

HOOKIPA Pharma’s Eseba-vec Highlighted in SITC Late-Breaker

GlobeNewswire
·
12 Nov 2024

Beyond Cancer Presents Promising Preclinical Data on Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) Therapy at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

GlobeNewswire
·
11 Nov 2024

While individual investors own 26% of SITC International Holdings Company Limited (HKG:1308), private companies are its largest shareholders with 41% ownership

Simply Wall St.
·
11 Nov 2024

Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting

GlobeNewswire
·
09 Nov 2024

Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

GlobeNewswire
·
08 Nov 2024

BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference

GlobeNewswire
·
08 Nov 2024

Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

GlobeNewswire
·
08 Nov 2024

Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting

GlobeNewswire
·
08 Nov 2024

Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS

GlobeNewswire
·
07 Nov 2024

MiNK’s iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024

GlobeNewswire
·
07 Nov 2024

IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting

GlobeNewswire
·
07 Nov 2024

Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting

GlobeNewswire
·
07 Nov 2024

Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

GlobeNewswire
·
07 Nov 2024

Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC

GlobeNewswire
·
07 Nov 2024

Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting

GlobeNewswire
·
05 Nov 2024

Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

GlobeNewswire
·
05 Nov 2024

HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024

GlobeNewswire
·
31 Oct 2024

NAYA Biosciences to Present Translational Insights to Support Phase I/IIa Clinical Trials for its GPC3-Targeting NK Engager Bispecific Antibody at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

GlobeNewswire
·
31 Oct 2024